Lidocaine; Tetracaine Patent Expiration

Lidocaine; Tetracaine was first introduced by Galen Specialty Pharma Us Llc in its drug Synera on Jun 23, 2005. Another drug containing Lidocaine; Tetracaine is Pliaglis. 2 different companies have introduced drugs containing Lidocaine; Tetracaine.


Lidocaine; Tetracaine Patents

Given below is the list of patents protecting Lidocaine; Tetracaine, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Pliaglis US10350180 Solid-forming local anesthetic formulations for pain control Jan 14, 2031 Crescita Therap
Pliaglis US10603293 Solid-forming local anesthetic formulations for pain control Jan 14, 2031 Crescita Therap
Pliaglis US10751305 Solid-forming topical formulations for pain control Jan 14, 2031 Crescita Therap
Synera US6465709 Exothermic bandage Jul 07, 2020

(Expired)

Galen Specialty
Pliaglis US6528086 Methods and apparatus for drug delivery involving phase changing formulations Sep 28, 2019

(Expired)

Crescita Therap
Pliaglis US5919479 Noninvasive dermal anesthetics Jul 28, 2015

(Expired)

Crescita Therap
Synera US5658583 Apparatus and methods for improved noninvasive dermal administration of pharmaceuticals Jul 28, 2015

(Expired)

Galen Specialty
Synera US5919479 Noninvasive dermal anesthetics Jul 28, 2015

(Expired)

Galen Specialty
Synera US6306431 Apparatus for heating to a desired temperature for improved administration of pharmaceutically active compounds Jul 28, 2015

(Expired)

Galen Specialty
Synera US6465006 Method for facilitating absorption of pharmaceutically active compounds Jul 28, 2015

(Expired)

Galen Specialty
Synera US6546281 Integrated apparatus for controlled heat aided dermal drug delivery Jul 28, 2015

(Expired)

Galen Specialty
Synera US6780426 Method and apparatus for improved heat controlled administration of pharmaceuticals Jul 28, 2015

(Expired)

Galen Specialty



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Lidocaine; Tetracaine's patents.

Given below is the list recent legal activities going on the following patents of Lidocaine; Tetracaine.

Activity Date Patent Number
Patent litigations
Expire Patent 16 Sep, 2016 US6780426
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 04 Mar, 2008 US6780426
Recordation of Patent Grant Mailed 24 Aug, 2004 US6780426
Patent Issue Date Used in PTA Calculation 24 Aug, 2004 US6780426
Issue Notification Mailed 05 Aug, 2004 US6780426
Receipt into Pubs 23 Jul, 2004 US6780426
Dispatch to FDC 21 Jul, 2004 US6780426
Application Is Considered Ready for Issue 02 Jul, 2004 US6780426
Issue Fee Payment Received 14 Jun, 2004 US6780426
Issue Fee Payment Verified 14 Jun, 2004 US6780426


Lidocaine; Tetracaine's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List